Table 1 Patient demographic and clinical characteristics.

From: Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status

Characteristics

Total cohort (N = 139) N (%)

TIM3 expression

P value

Positive (N = 35)

Negative (N = 104)

Age at TURP, Median (range)

66 (36–87)

64 (36–82)

68 (43–87)

0.270a

cT stage at TURP

   

0.056b

 T2

59 (42.4)

15 (42.9)

44 (42.3)

 

 T3

24 (17.3)

8 (22.9)

16 (15.4)

 

 T4

24 (17.3)

9 (25.7)

15 (14.4)

 

 Tx

32 (23.0)

3 (8.6)

29 (27.9)

 

cN stage at TURP

   

0.607b

 N0

49 (35.3)

14 (40.0)

35 (33.7)

 

 N1

62 (44.6)

16 (45.7)

46 (44.2)

 

 Nx

28 (20.1)

5 (14.3)

23 (22.1)

 

Gleason Score

   

0.392b

 6

5 (3.6)

0 (0.0)

5 (4.8)

 

 7

18 (12.9)

6 (17.1)

12 (11.5)

 

 ≥8

116 (83.5)

29 (82.9)

87 (83.7)

 

PSA at TURP, Median (range)

71.80 (0.38–5000)

108 (3.39–1535)

62.06 (0.38–5000)

0.957a

mPCa subtype

   

0.011 b

 mHSPC

94 (67.6)

30 (85.7)

64 (61.5)

 

 mCRPC

45 (32.4)

5 (14.3)

40 (38.5)

 

ADT prior to TURP

   

0.497b

 Yes

127 (91.4)

31 (88.6)

96 (92.3)

 

 No

12 (8.6)

4 (11.4)

8 (7.7)

 

Chemotherapy

   

1.000b

 Yes

44 (31.7)

11 (31.4)

33 (31.7)

 

 No

95 (68.3)

24 (68.6)

71 (68.3)

 

Radiotherapy

   

1.000b

 Yes

5 (3.6)

1 (2.9)

4 (3.8)

 

 No

134 (96.4)

34 (97.1)

100 (96.2)

 
  1. aStudent’s t test. bFisher exact test (based on Chi-square). TURP: transurethral resection of the prostate. ADT: androgen-deprived therapy.
Back to article page